Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)Jinane Zitouni, S. Mallet, E. Mahé et al.|Pediatric Drugs|2022Cited by 13